ATE450257T1 - Hydrophile molekulardisperse lösungen von carvedilol - Google Patents

Hydrophile molekulardisperse lösungen von carvedilol

Info

Publication number
ATE450257T1
ATE450257T1 AT01929462T AT01929462T ATE450257T1 AT E450257 T1 ATE450257 T1 AT E450257T1 AT 01929462 T AT01929462 T AT 01929462T AT 01929462 T AT01929462 T AT 01929462T AT E450257 T1 ATE450257 T1 AT E450257T1
Authority
AT
Austria
Prior art keywords
carvedilol
hydrophilic molecular
molecular disperse
disperse solutions
solutions
Prior art date
Application number
AT01929462T
Other languages
English (en)
Inventor
Rolf-Dieter Gabel
Alexander Wirl
Walter Preis
Guenter Neugebauer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE450257(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE450257T1 publication Critical patent/ATE450257T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01929462T 2000-04-03 2001-03-28 Hydrophile molekulardisperse lösungen von carvedilol ATE450257T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00107093 2000-04-03
PCT/EP2001/003502 WO2001074357A1 (en) 2000-04-03 2001-03-28 Hydrophilic molecular disperse solutions of carvedilol

Publications (1)

Publication Number Publication Date
ATE450257T1 true ATE450257T1 (de) 2009-12-15

Family

ID=8168348

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01929462T ATE450257T1 (de) 2000-04-03 2001-03-28 Hydrophile molekulardisperse lösungen von carvedilol

Country Status (24)

Country Link
US (3) US20010036959A1 (de)
EP (1) EP1272179B1 (de)
JP (1) JP2003528915A (de)
KR (1) KR100478793B1 (de)
CN (1) CN1189171C (de)
AR (1) AR029825A1 (de)
AT (1) ATE450257T1 (de)
AU (2) AU2001256227B2 (de)
BR (1) BR0109779A (de)
CA (1) CA2401910C (de)
CZ (1) CZ20023625A3 (de)
DE (1) DE60140662D1 (de)
HR (1) HRP20020777A2 (de)
HU (1) HUP0300342A3 (de)
IL (1) IL151642A0 (de)
MA (1) MA26888A1 (de)
MX (1) MXPA02009725A (de)
NO (1) NO20024733L (de)
NZ (1) NZ521232A (de)
PL (1) PL358103A1 (de)
RU (1) RU2248204C2 (de)
WO (1) WO2001074357A1 (de)
YU (1) YU72602A (de)
ZA (1) ZA200207304B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69917618T2 (de) * 1998-04-03 2005-06-23 Egalet A/S Zusammensetzung mit kontrollierter wirkstoff-freisetzung
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP2957281A1 (de) * 2001-09-21 2015-12-23 Egalet Ltd. Polymer-freigabe-system
EP1429734B1 (de) * 2001-09-21 2007-12-26 Egalet A/S Feste dispersionen mit kontrollierter freisetzung von carvedilol
ES2291503T3 (es) * 2001-09-28 2008-03-01 F. Hoffmann-La Roche Ag Formas pseudopolimorficas de carvedilol.
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
CA2484621A1 (en) * 2002-05-03 2003-11-13 Smithkline Beecham Pharmco Puerto Rico, Inc. Carvedilol formulations
AU2003248746B2 (en) * 2002-06-27 2009-01-08 Smithkline Beecham (Cork) Limited Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
CA2492084A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
US8877241B2 (en) * 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
EP2186510B1 (de) * 2003-03-26 2013-07-10 Egalet Ltd. Matrixzubereitungen für die kontrollierte Darreichung von Arzneistoffen
BRPI0412329A (pt) * 2003-07-09 2006-09-05 Chong Kun Dang Pharm Corp dispersão sólida de tacrolimus e método de processar a mesma
AU2004267909B2 (en) 2003-08-29 2008-12-18 Veloxis Pharmaceuticals, Inc. Modified release compositions comprising tacrolimus
SI1663216T1 (sl) * 2003-08-29 2012-03-30 Veloxis Pharmaceuticals As Sestavek z modificiranim sproščanjem ki vsebuje takrolimus
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
US7750036B2 (en) * 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
CA2551254A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
WO2006128471A2 (en) * 2005-06-03 2006-12-07 Egalet A/S A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20080138404A1 (en) * 2006-12-06 2008-06-12 Biovail Laboratories International S.R.L. Extended release formulations of carvedilol
CA2674536C (en) * 2007-01-16 2016-07-26 Egalet A/S Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
WO2009110004A1 (en) 2008-03-04 2009-09-11 Lupin Limited Stable pharmaceutical compositions qf carvedilol
ES2330404B1 (es) * 2008-05-19 2010-09-22 Universidad De Barcelona Solucion acuosa para la preservacion de tejidos y organos.
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (de) 2009-06-24 2012-05-02 Egalet Ltd. Retard-formulierungen
WO2011154009A1 (en) * 2010-06-10 2011-12-15 Lifecycle Pharma A/S Composition comprising an active principle in an amorphous form and a porous adsorbent material
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
AU741821B2 (en) * 1997-03-11 2001-12-13 Arakis Limited Dosage forms comprising separate portions of R- and S-enantiomers
DE19809242A1 (de) * 1998-03-05 1999-09-09 Basf Ag Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE19816036A1 (de) * 1998-04-09 1999-10-14 Roche Diagnostics Gmbh Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
US6852337B2 (en) * 1998-04-09 2005-02-08 Roche Diagnostics Gmbh Carvedilol-galenics
US6664284B2 (en) * 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
PL371409A1 (en) * 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation

Also Published As

Publication number Publication date
CN1189171C (zh) 2005-02-16
KR20030019339A (ko) 2003-03-06
JP2003528915A (ja) 2003-09-30
HUP0300342A3 (en) 2005-07-28
CN1420771A (zh) 2003-05-28
PL358103A1 (pl) 2004-08-09
DE60140662D1 (de) 2010-01-14
AR029825A1 (es) 2003-07-16
YU72602A (sh) 2005-03-15
NZ521232A (en) 2004-05-28
MA26888A1 (fr) 2004-12-20
RU2248204C2 (ru) 2005-03-20
IL151642A0 (en) 2003-04-10
WO2001074357A1 (en) 2001-10-11
US20030004205A1 (en) 2003-01-02
HUP0300342A2 (hu) 2003-06-28
AU2001256227B2 (en) 2005-09-01
CA2401910C (en) 2008-04-15
US20050271721A1 (en) 2005-12-08
AU5622701A (en) 2001-10-15
US20010036959A1 (en) 2001-11-01
ZA200207304B (en) 2003-12-11
CZ20023625A3 (cs) 2003-04-16
KR100478793B1 (ko) 2005-03-24
CA2401910A1 (en) 2001-10-11
RU2002129571A (ru) 2004-03-27
MXPA02009725A (es) 2003-03-27
HRP20020777A2 (en) 2004-12-31
EP1272179A1 (de) 2003-01-08
BR0109779A (pt) 2003-01-21
NO20024733D0 (no) 2002-10-02
NO20024733L (no) 2002-10-02
EP1272179B1 (de) 2009-12-02

Similar Documents

Publication Publication Date Title
ATE450257T1 (de) Hydrophile molekulardisperse lösungen von carvedilol
DE69939575D1 (de) Entdeckung von Diensten in unmittelbarer Nähe
DE60018429D1 (de) Herstellung von poly(trimethylenterephthalat)
DK1317813T3 (da) Multibærermodtager
NO20025724L (no) Selvgående overflatebehandlende anordning
FI20000616A0 (fi) Tilaajatietojen päivitys
DE60136181D1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
DE60105996D1 (de) Konzentrierte lösungen von carvedilol
FI20000732L (fi) Tilaajan autentikaatio
DE60015065D1 (de) Schaltbares, flüssigkeitsgefülltes und schwingungsisolierendes Lager
DE60032684D1 (de) Mehrträgermodulation
NO20013337L (no) Ny behandling
DE60120028D1 (de) Kontaktanordnung
IT1318619B1 (it) Procedimento e dispositivo di trattamento elettrochimico.
DE60007360T2 (de) Amorphe modifikation von torasemid
DE19983090T1 (de) Polyacrylnitrilpolymer-Behandlung
BR9914722A (pt) Derivados de anticonvulsivo úteis no tratamento de dependência, vìcio e abuso do álcool
FI20000695L (fi) Viestin käsittely
DE60125035D1 (de) Behandlung von plasmid-haltigen lösungen
NO20024575L (no) Fluorescerende kontaktlinser
EP1390408A4 (de) Molekularer marker
DE50106271D1 (de) Abtragen von kontaktstellen (de-bumping)
FI20002858A7 (fi) Autentikointi tietoliikenteessä
ES1049942Y (es) Pareja de zocalo y portalamparas.
SK3308U (sk) Konzolová zabezpečovacia značka

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties